
Gilead has revealed it is to acquire the immunology firm Forty Seven in a deal valued at $95.50 per share …

Forty Seven, a spinout from Stanford University, has had a busy few days – first announcing that it had filed …
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact

